1. Wang Y, Sun Y, Yang XY, et al. Mobilised bone marrow‐derived cells accelerate wound healing. Int Wound J. 2013;10: 473-479.
2. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3: 687-694.
3. Nassar D, Batteux F, Raymond K, et al. Delayed healing of sickle cell ulcers is due to impaired angiogenesis and CXCL12 secretion in skin wounds. J Invest Dermatol. 2016;136: 497-506.
4. Laiva AL, O'Brien FJ and Keogh MB. Innovations in gene and growth factor delivery systems for diabetic wound healing. J Tissue Eng Regen Med. 2018;12: e296-e312.
5. Dinh T, Tecilazich F, Kafanas A, et al. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. 2012;61: 2937-2947.
6. Hunt DL. Diabetes: foot ulcers and amputations. BMJ Clin Evidence. 2011;2011:
7. Zelen CM, Orgill DP, Serena T, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Int Wound J. 2017;14: 307-315.
8. Jiang Y, Chen B, Liu Y, et al. Effect of collagen scaffold with adipose-derived stromal vascular fraction cells on diabetic wound healing: A study in a diabetic porcine model. Tissue Eng Regen Med. 2013;10: 192-199.
9. Hart CE, Loewen-Rodriguez A and Lessem J. Dermagraft: use in the treatment of chronic wounds. Adv Wound Care. 2012;1: 138-141.
10. Dinh TL and Veves A. The efficacy of Apligraf in the treatment of diabetic foot ulcers. Plast Reconst Surg. 2006;117: 152S-157S.
11. Lopes L, Setia O, Aurshina A, et al. Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research. Stem Cell Res Ther. 2018;9: 188.
12. Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Prac. 2011;92: 26-36.
13. Lee HC, An SG, Lee HW, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia. Circulation J. 2012 1204091686-1204091686.
14. Li Q, Zhang A, Tao C, et al. The role of SDF-1-CXCR4/CXCR7 axis in biological behaviors of adipose tissue-derived mesenchymal stem cells in vitro. Biochem Biophys Res Commun. 2013;441: 675-680.
15. Kim SM, Kim YH, Jun YJ, et al. The effect of diabetes on the wound healing potential of adipose‐tissue derived stem cells. Int Wound J. 2016;13: 33-41.
16. Kim H, Han JW, Lee JY, et al. Diabetic mesenchymal stem cells are ineffective for improving limb ischemia due to their impaired angiogenic capability. Cell Transplant. 2015;24: 1571-1584.
17. Massee M, Chinn K, Lim JJ, et al. Type I and II diabetic adipose-derived stem cells respond in vitro to dehydrated human amnion/chorion membrane allograft treatment by increasing proliferation, migration, and altering cytokine secretion. Adv Wound Care. 2016;5: 43-54.
18. Cianfarani F, Toietta G, Di Rocco G, et al. Diabetes impairs adipose tissue–derived stem cell function and efficiency in promoting wound healing. Wound Repair Regen. 2013;21: 545-553.
19. Peng Z, Yang X, Qin J, et al. Glyoxalase‐1 overexpression reverses defective proangiogenic function of diabetic adipose‐derived stem cells in streptozotocin‐induced diabetic mice model of critical limb ischemia. Stem Cells Trans Med. 2017;6: 261-271.
20. O'Brien FJ. Biomaterials & scaffolds for tissue engineering. Mater Today. 2011;14: 88-95.
21. Wang C, Ma L and Gao C. Design of gene-activated matrix for the repair of skin and cartilage. Polym J. 2014;46: 476-482.
22. Lackington WA, Raftery RM and O'Brien FJ. In vitro efficacy of a gene-activated nerve guidance conduit incorporating non-viral PEI-pDNA nanoparticles carrying genes encoding for NGF, GDNF and c-Jun. Acta Biomater. 2018;75: 115-128.
23. Walsh DP, Raftery RM, Castaño IM, et al. Transfection of autologous host cells in vivo using gene activated collagen scaffolds incorporating star-polypeptides. J Control Release. 2019;304: 191-203.
24. Laiva AL, Raftery RM, Keogh MB, et al. Pro-angiogenic impact of SDF-1α gene-activated collagen-based scaffolds in stem cell driven angiogenesis. Int J Pharm. 2018;544: 372-379.
25. Raftery RM, Tierney EG, Curtin CM, et al. Development of a gene-activated scaffold platform for tissue engineering applications using chitosan-pDNA nanoparticles on collagen-based scaffolds. J Control Release. 2015;210: 84-94.
26. Kolakshyapati P, Li X, Chen C, et al. Gene-activated matrix/bone marrow-derived mesenchymal stem cells constructs regenerate sweat glands-like structure in vivo. Sci Rep. 2017;7: 1-13.
27. Cassidy FC, Shortiss C, Murphy CG, et al. Impact of Type 2 Diabetes Mellitus on Human Bone Marrow Stromal Cell Number and Phenotypic Characteristics. Int J Mol Sci. 2020;21: 2476.
28. Nishiguchi MA, Spencer CA, Leung DH, et al. Aging suppresses skin-derived circulating SDF1 to promote full-thickness tissue regeneration. Cell Rep. 2018;24: 3383-3392. e5.
29. Holm JS, Toyserkani NM and Sorensen JA. Adipose-derived stem cells for treatment of chronic ulcers: current status. Stem Cell Res Ther. 2018;9: 142.
30. Lohana P, Hassan S and Watson S. Integra™ in burns reconstruction: our experience and report of an unusual immunological reaction. Ann Burn Fire Disasters. 2014;27: 17.
31. Driver VR, Lavery LA, Reyzelman AM, et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen. 2015;23: 891-900.
32. Gallagher KA, Liu Z-J, Xiao M, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1α. J Clin Invest. 2007;117: 1249-1259.
33. Toksoy A, Müller V, Gillitzer R, et al. Biphasic expression of stromal cell‐derived factor‐1 during human wound healing. Brit J Dermatol. 2007;157: 1148-1154.
34. O’Brien FJ, Harley BA, Yannas IV, et al. Influence of freezing rate on pore structure in freeze-dried collagen-GAG scaffolds. Biomaterials 2004;25: 1077-1086.
35. Haugh MG, Murphy CM and O'Brien FJ. Novel freeze-drying methods to produce a range of collagen–glycosaminoglycan scaffolds with tailored mean pore sizes. Tissue Eng Part C Methods. 2010;16: 887-894.
36. Kim H-S. Role of insulin-like growth factor binding protein-3 in glucose and lipid metabolism. Ann Pediatr Endocrinol Metabol. 2013;18: 9.
37. Wu J, Strawn TL, Luo M, et al. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk. Arterioscler Thromb Vasc Biol. 2015;35: 111-120.
38. Akahane T, Akahane M, Shah A, et al. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res. 2004;301: 158-167.
39. Rohrs JA, Sulistio CD and Finley SD. Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissue. NPJ Syst Biol Appl. 2016;2: 16030.
40. Michalczyk ER, Chen L, Fine D, et al. Pigment Epithelium-Derived Factor (PEDF) as a Regulator of Wound Angiogenesis. Sci Rep. 2018;8: 11142.
41. Benest AV, Kruse K, Savant S, et al. Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS One. 2013;8: e70459.
42. Rajagopal S, Kim J, Ahn S, et al. β-arrestin-but not G protein-mediated signaling by the “decoy” receptor CXCR7. Proc Natl Acad Sci. 2010;107: 628-632.
43. Bitar MS. Diabetes Impairs Angiogenesis and Induces Endothelial Cell Senescence by Up-Regulating Thrombospondin-CD47-Dependent Signaling. Int J Mol Sci. 2019;20: 673.
44. Hsiao C-T, Cheng H-W, Huang C-M, et al. Fibronectin in cell adhesion and migration via N-glycosylation. Oncotarget 2017;8: 70653.
45. Ramos-Lewis W, LaFever KS and Page-McCaw A. A scar-like lesion is apparent in basement membrane after wound repair in vivo. Matrix Biol. 2018;74: 101-120.
46. Rennert RC, Sorkin M, Januszyk M, et al. Diabetes impairs the angiogenic potential of adipose-derived stem cells by selectively depleting cellular subpopulations. Stem Cell Res Ther. 2014;5: 79.
47. Dzhoyashvili NA, Efimenko AY, Kochegura TN, et al. Disturbed angiogenic activity of adipose-derived stromal cells obtained from patients with coronary artery disease and diabetes mellitus type 2. J Trans Med. 2014;12: 337.
48. Werner S and Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83: 835-870.
49. Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16: 585-601.
50. Park S-R, Kim J-W, Jun H-S, et al. Stem cell secretome and its effect on cellular mechanisms relevant to wound healing. Mol Ther. 2018;26: 606-617.
51. Perry L, Landau S, Flugelman MY, et al. Genetically engineered human muscle transplant enhances murine host neovascularization and myogenesis. Commun Biol. 2018;1: 1-13.
52. Wood S, Jayaraman V, Huelsmann EJ, et al. Pro-inflammatory chemokine CCL2 (MCP-1) promotes healing in diabetic wounds by restoring the macrophage response. PloS One. 2014;9: e91574.
53. Galkowska H, Wojewodzka U and Olszewski WL. Low recruitment of immune cells with increased expression of endothelial adhesion molecules in margins of the chronic diabetic foot ulcers. Wound Repair Regen. 2005;13: 248-254.
54. Engelhardt E, Toksoy A, Goebeler M, et al. Chemokines IL-8, GROα, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol. 1998;153: 1849-1860.
55. Weinheimer-Haus EM, Judex S, Ennis WJ, et al. Low-intensity vibration improves angiogenesis and wound healing in diabetic mice. PloS One. 2014;9: e91355.
56. Ellison DD, Suhail Y, Afzal J, et al. Dynamic secretome of bone marrow-derived stromal cells reveals a cardioprotective biochemical cocktail. Proc Natl Acad Sci. 2019;116: 14374-14383.
57. Kowalski K, Brzoska E and Ciemerych MA. The role of CXC receptors signaling in early stages of mouse embryonic stem cell differentiation. Stem Cell Res. 2019;41: 101636.
58. Liu H, Liu S, Li Y, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PloS One. 2012;7: e34608.
59. Wynn RF, Hart CA, Corradi-Perini C, et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood. 2004;104: 2643-2645.
60. Wang E, Jarrah A, Benard L, et al. Deletion of CXCR4 in cardiomyocytes exacerbates cardiac dysfunction following isoproterenol administration. Gene Ther. 2014;21: 496-506.
61. Albersen M, Berkers J, Dekoninck P, et al. Expression of a distinct set of chemokine receptors in adipose tissue‐derived stem cells is responsible for in vitro migration toward chemokines appearing in the major pelvic ganglion following cavernous nerve injury. Sex Med. 2013;1: 3-15.
62. Hoffmann F, Müller W, Schütz D, et al. Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues. J Biol Chem. 2012;287: 28362-28377.
63. Lisignoli G, Cristino S, Piacentini A, et al. Hyaluronan‐based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54. J Cell Physiol. 2006;207: 364-373.
64. Goessler UR, Bugert P, Bieback K, et al. Integrin expression in stem cells from bone marrow and adipose tissue during chondrogenic differentiation. Int J Mol Med. 2008;21: 271-279.
65. Popov C, Radic T, Haasters F, et al. Integrins α 2 β 1 and α 11 β 1 regulate the survival of mesenchymal stem cells on collagen I. Cell Death Dis. 2011;2: e186-e186.
66. Liu H, Xue W, Ge G, et al. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs. Biochem Biophys Res Commun. 2010;401: 509-515.
67. Liu L, Chen J-X, Zhang X-W, et al. Chemokine receptor 7 overexpression promotes mesenchymal stem cell migration and proliferation via secreting Chemokine ligand 12. Sci Rep. 2018;8: 1-10.
68. Lee YJ, Baek SE, Lee S, et al. Wound‐healing effect of adipose stem cell‐derived extracellular matrix sheet on full‐thickness skin defect rat model: Histological and immunohistochemical study. Int Wound J. 2019;16: 286-296.
69. Lee KB, Choi J, Cho SB, et al. Topical embryonic stem cells enhance wound healing in diabetic rats. J Orthop Res. 2011;29: 1554-1562.
70. Roy DC, Mooney NA, Raeman CH, et al. Fibronectin matrix mimetics promote full-thickness wound repair in diabetic mice. Tissue Eng Part A. 2013;19: 2517-2526.
71. Hocking DC, Brennan JR and Raeman CH. A Small Chimeric Fibronectin Fragment accelerates dermal Wound repair in diabetic mice. Adv Wound Care. 2016;5: 495-506.
72. Qiu Z, Kwon A-H and Kamiyama Y. Effects of plasma fibronectin on the healing of full-thickness skin wounds in streptozotocin-induced diabetic rats. J Surg Res. 2007;138: 64-70.
73. Damås JK, Wæhre T, Yndestad A, et al. Stromal Cell–Derived Factor-1α in Unstable Angina: Potential Antiinflammatory and Matrix-Stabilizing Effects. Circulation. 2002;106: 36-42.